Adaptimmune Therapeutics PLC Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Adaptimmune Therapeutics PLC quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2015 to Q2 2024.
  • Adaptimmune Therapeutics PLC Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $3.06M, a 20.3% decline year-over-year.
  • Adaptimmune Therapeutics PLC Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $12.4M, a 5.36% decline year-over-year.
  • Adaptimmune Therapeutics PLC annual Share-based Payment Arrangement, Expense for 2023 was $11.8M, a 35.5% decline from 2022.
  • Adaptimmune Therapeutics PLC annual Share-based Payment Arrangement, Expense for 2022 was $18.2M, a 11.6% decline from 2021.
  • Adaptimmune Therapeutics PLC annual Share-based Payment Arrangement, Expense for 2021 was $20.6M, a 98.1% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $12.4M $3.06M -$780K -20.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $13.2M $3.1M +$1.43M +85.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $11.8M $3.08M -$869K -22% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 $12.6M $3.18M -$480K -13.1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $13.1M $3.84M -$1.21M -23.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $14.3M $1.68M -$3.91M -70% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $18.2M $3.95M -$881K -18.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 $19.1M $3.66M -$1.36M -27% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $20.5M $5.05M -$404K -7.41% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $20.9M $5.59M +$252K +4.72% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $20.6M $4.83M +$1.77M +57.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 $18.9M $5.02M +$1.74M +53% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $17.1M $5.45M +$2.83M +108% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $14.3M $5.33M +$3.89M +268% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $10.4M $3.06M +$504K +19.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-06
Q3 2020 $9.91M $3.28M +$1.46M +80.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $8.45M $2.62M -$572K -17.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $9.02M $1.45M -$2.03M -58.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $11.1M $2.56M -$851K -25% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 $11.9M $1.82M -$2.22M -55% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $14.1M $3.2M -$883K -21.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $15M $3.48M -$1.19M -25.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 $16.2M $3.41M -$565K -14.2% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $16.8M $4.04M +$1.97M +95.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $14.8M $4.08M +$2.01M +96.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 $12.8M $4.67M +$1.99M +73.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-06
Q4 2017 $10.8M $3.97M +$1.95M +96.5% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 $8.85M $2.07M -$214K -9.36% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $9.07M $2.07M -$367K -15% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $9.43M $2.69M +$612K +29.5% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $8.82M $2.02M Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 $2.29M +$885K +63.2% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-02
Q2 2016 $2.44M -$2.37M -49.3% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $2.07M +$592K +39.9% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q3 2015 $1.4M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 $4.81M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 $1.48M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.